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Objective: To investigate the inﬂuence of CD133+ expression on patients' survival and
resistance of CD133+ cells to anti-tumor agents in gastric cancer (GC).
Methods: Inﬂuence of CD133 expression on prognosis was analyzed employing sam-
ples from patients with GC. GC cell lines were utilized to separate CD133+ and CD133−
subpopulations by immunomagnetic separation and to analyze the biological features of
two subpopulations in vitro and in vivo, especially in resistant to anti-tumor reagents and
its apoptotic mechanism.
Results: The lower CD133+ group showed a signiﬁcantly better survival compared with
the higher CD133+ group. The highest content of CD133+ subpopulations for KATO-III
cells had stronger proliferative ability than CD133− subpopulations. A single CD133+ cell
was capable of generating new cell colony and the tumorigenicity rate in nude mice was
100% for CD133+ clonal spheres or for CD133+ cells, but 0% for CD133− cells.
Furthermore, the higher expression levels of Oct-4, Sox-2, Musashi-1 and ABCG2 in
CD133+ clonal spheres were identiﬁed compared with CD133+ cells or CD133− cells.
Under the treatment of anti-tumor reagents, CD133+ cells had lower suppression rates
compared with CD133− cells while lower level of Bcl-2 and higher level of Bax were
found in CD133+ cells compared with CD133− cells.
Conclusions: The patients with lower CD133+ expression had a better survival. Enriched
CD133+ cells in clonal sphere shared the ability to be self-renewable, proliferative,
tumorigenic and resistant to anti-tumor agents as probably regulated by Bcl-2 and Bax.1. Introduction
Tumor invasion and metastasis is considered to be the pri-
mary cause of death for patients with gastric cancer (GC). GC
frequently recurs and metastasizes following the seemingly
successful initial treatment, with a recurrence rate of approxi-
mately 40% within 2–3 years of surgical treatment. Furthermore,
it has a ﬁve-year survival rate of only 25% [1,2].It is conventionally believed that tumorigenesis results from
the homogeneous multiplication of all tumor cells. Primary tu-
mor cells enter into clonal proliferation due to the continuous
mutations in genetically susceptible key genes regulating cell
growth [3]. However, accumulating evidences reveal that
tumorigenesis results from cell differentiation disorder
involving multiple genes and multiple steps in a
heterogeneous progression [4]. It is hypothesized that
malignant tumors are hierarchically composed of multiple
heterogeneous cell subpopulations. Among these
subpopulations, tumor initiating cells (TICs) are a speciﬁc
subpopulation expressing single or multiple cell surface
markers, which can initiate and construct tumor histological
phenotype. Additionally, TICs determine the drug resistance
and the tumor invasiveness/metastasis [5]. CD34+/CD38+ cell
subpopulation has been demonstrated to duplicate a leukemia
animal model in immunodeﬁcient severe combined
immunodeﬁciency mice, which suggests the long life span andan open access article under the CC BY-NC-ND
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man myeloblastic leukemia derives from stem cells [6]. TICs
with CD133+ expression have been subsequently identiﬁed in
various solid tumors, such as breast cancer, brain tumor,
prostate cancer, malignant melanoma, colon cancer, liver
cancer, pancreatic cancer and head and neck squamous cell
carcinoma, though CD133+ cancerous cells have not been
classiﬁed as cancer stem cells of stomach until now [7–14].
It has been possible to enrich and characterize TICs through
the speciﬁc cell surface markers. However, the GC TICs are yet
to be isolated successfully due to the limitation in current sep-
aration technique and biomarkers. Smith et al. reported that the
gastrointestinal tumor cells expressed CD133 receptors were
antagonized by the anti-CD133 antibodies in combination with
chemotherapeutic agents and suppressed the GC xenograft
growth in nude mice [15]. This ﬁnding implies that CD133+ cells
probably possess the tumorigenic potential of TICs.
Furthermore, our previous study showed that CD133 was
related to chemoresistance in GC cells [16].
In this study, more clinical specimens were included to
quantify the CD133 expression in primary lesion of GC tissue in
relation to prognosis, which was not deluded in the CD133
protein level in our preliminary study [17]. To obtain a larger
amount of CD133+ cells for further steps of biological,
tumorigenic and resistant to anti-tumor investigations, we also
examined the percentage of CD133+ cell subpopulation among
four kinds of GC cell lines varying in cell differentiation by ﬂow
cytometry and attempted to enrich CD133+ cells through
immunomagnetic separation combined with serum-free culture
(i.e. ﬂoating culture). Due to the highest percentage of CD133+
cells in KATO-III cell lines among these four GC cell lines, the
enriched CD133+ cells from KATO-III were applied for further
evaluations regarding proliferative potential, colony-forming
capacity, tumorigenic capability in vivo, the mRNA expres-
sions of relative stem cell markers and resistance to anti-tumor
drug including the suppression rate of cell growth and mRNA
expressions of Bcl-2 and Bax regulating apoptosis. These ﬁnd-
ings from such investigations are beneﬁcial to advance our
knowledge about CD133+ cells speciﬁcities probably like TICs
to some extent and resistant mechanism of anti-tumor drug
regarding GC CD133+ cells.
2. Materials and methods
2.1. Clinical specimens, cells and reagents
Primary lesions of GC and paired peri-cancer gastric tissue
(at a place of 5 cm far from tumor margin as non-cancerous
tissue identiﬁed by pathological examination) were harvested
from histologically documented GC patients who underwent
deﬁnitive surgery at our hospital from January 2009 to
December 2010. None of these patients accepted any preoper-
ative chemotherapy or radiotherapy. Chemotherapeutic treat-
ment of 5-ﬂuorouracil (5-FU), cisplatin and leucovorin was
applied 6 times as a protocol of 3 weeks for each patient after
surgery. All patients were followed up for 1–37 months until
February 2012. This study was approved by ethical committee
of our hospital before its start and preoperative informed consent
was obtained from each patient registered in this study in
accordance with institutional guidance.
The cell line KATO-III, SGC-7901, AGS and MKN-45
were purchased from American Type Culture Collection.The Roswell Park Memorial Institute 1640 medium was pur-
chased from Gibco, US. Human epidermal growth factor
(hEGF) and human basic ﬁbroblast growth factor (bFGF) were
purchased from PeproTech, US. The CD133 separation kit,
mouse anti-human CD133 monoclonal antibody and CD133-
PE ﬂow antibody were purchased from Miltenyi, Germany.
Horseradish peroxidase-labeled goat-anti-mouse secondary
antibody was purchased from Jackson, US. The target primers
were purchased from Sangon Biotech (Shanghai) Co., Ltd.,
Shanghai, China. The RT-PCR assay kit was purchased
from Takara, Japan. The ABC kit was purchased from Santa
Cruz, US and the CCK-8 assay kit was purchased from
Cayman, US.
2.2. Semi-quantitative RT-PCR
The total RNA was extracted using Trizol. RT-PCR assays
were performed as previously reported [16]. The experiments
were duplicated and independently run in triplicates.
2.3. Western blot assay
The western blot assay was performed as previously reported
[16]. The experiments were performed in duplicates and
independently repeated in triplicates.
2.4. Immunohistochemical assay
Immunohistochemical staining was performed using the
strept avidin–biotin complex method. Peri-cancer tissues from
the same patient with GC were used as negative control. Phos-
phate buffer saline (PBS) was used as blank control in
replacement of primary antibodies and the positive samples
supplied by the vendor were used as positive controls [16].
2.5. Cell culture and ﬂow cytometry
KATO-III cells were cultured in ATCC containing 20% fetal
bovine serum. The SGC7901, AGS and MKN-45 cells were
cultured in Roswell Park Memorial Institute 1640 containing
10% fetal bovine serum. All cells lines were maintained in a
humidiﬁed atmosphere at 37 C with 5% CO2. They were rinsed
in PBS and were suspended again to a density of 1 × 105 cells/
mL and then 300 mL of this cell suspension was incubated with
FcR blocking reagent (100 mL) and CD133-PE antibody
(100 mL) for 30 min at 4 C in darkness. The immunoglobulin
G-PE antibody was used as negative control. The cell suspen-
sion (500 mL) was rinsed twice with PBS to determine the
percentage of CD133+ cell subpopulation with ﬂow cytometry
(Becton Dickinson, US) [18].
2.6. Immunomagnetic separation (IMS)
KATO-III cells were harvested at a density of 1 × 107 cells/
mL. The cell suspension (300 mL) was separated using Mini-
MACS as instructed by the vendor [19]. The CD133+ and
CD133-negative (CD133−) cells were resuspended in serum-
free ATCC media supplemented with 20 ng/mL hEGF and
10 ng/mL bFGF. Flow cytometry was used to determine the
percentages of CD133+ cell subpopulations prior to and
following the separation.
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Following the separation, CD133+ and CD133− cells were
resuspended in serum-free media supplemented with 20 ng/mL
hEGF and 10 ng/mL bFGF at a density of 1 × 104 cells/mL. The
cells were seeded in 96-well plates at a volume of 200 mL/well.
The cells were incubated with CCK-8 for 24 h and then the
absorbance at 450 nm was measured to calculate cell growth
rates.
2.8. Colony-forming assay
The CD133+ and CD133− cells were cloned through the
limiting dilution as previously reported [20]. The cells were
resuspended to a density of 500 cells/mL and were seeded in
96-well plates at a volume of approximately 2 mL/well. Under
an inverted phase-contrast microscope (Olympus, Japan), the
wells containing single cell were supplemented with 200 mL of
ATCC serum-free media with 20 ng/mL hEGF and 10 ng/mL
bFGF. The wells containing the clone cultures were appropriately
labeled and the cells were dissociated, collected and passaged
onto 24-well plates when the cells almost reached the conﬂuency.
2.9. RT-PCR of stem cell-associated markers
The sphere clone cells in CD133+ subset group and CD133−
subset group were collected for RT-PCR as previously reported
[17,21]. The primer sequences were presented in Table 1. The
experiments were duplicated and independently repeated in
triplicates.
2.10. Drug resistance testing and cell apoptosis-
associated gene proﬁling
Selected CD133+ and CD133− cells were resuspended in
serum-free ATCC media supplemented with 20 ng/mL hEGF
and 10 ng/mL bFGF at a density of 1 × 104 cells/mL. The cells
were seeded in 96-well plates at a volume of 200 mL per well.
Fluorouracil (5-FU, 5–20 mmol/L), cisplatin (5–20 mmol/L) and
etoposide (VP-16, 0.1–0.4 mmol/L) were supplemented inTable 1
Primers sequences and primary functions of stem cell-associated genes.
Genes Primers
Sox-2 Upstream 50-CAAGATGGCCCAGGAGAACC-30
Downstream 50-GCTGCGAGTAGGACATGCTGTA-30
Nanog Upstream 50-CAGCTGTGTGTACTCAATGATAGATT
Downstream 50-ACACCATTGCTATTCTTCGGCCAGTT
Oct-4 Upstream 50-GGCGTTCTCTTTGGAAAGGTGTTC-30
Downstream 50-CAAAGCTCCAGGTTCTCTTG-30
Musashi-1 Upstream 50-TAATTCCTGTCCAGCAGTCTC-30
Downstream 50-GAACCATCCCGTCCTGTATCAT-30
EGFR Upstream 50-TAACAAGCTCACGCAGTTGG-30
Downstream 50-GCCCTTCGCACTTCTTACAC-30
ABCG2 Upstream 50-GCGACCTGCCAATTTCAAAT-30
Downstream 50-AGCCAGTTGTAGGCTCATCCA-30
Bcl-2 Upstream 50-TTGGATCAGGGAGTTGGAAG-30
Downstream 50-TGTCCCTACCAACCAGAAGG-30
BAX Upstream 50-AAGAAGCTGAGCGAGTGT-30
Downstream 50-GGAGGAAGTCCAATGTC-30
GAPDH Upstream 50-ACGGATTTGGTCGTATTGGGCG-30
Downstream 50-CTCCTGGA AGATGGTGATGG-30triplicates for either concentration of each agent. Following 24 h
treatment, CCK-8 assay was performed to reﬂect the number of
viable cells and further cell growth suppression rates for each
chemotherapeutic agent. The cell growth suppression
rate = [(Ablank − Aexperiment − Azeroing)/
(Acontrol − Azeroing)] × 100% [21,22]. The cells were seeded in 6-
well plates (2 mL/well) and were treated with 10 mmol/L 5-FU,
10 mmol/L cisplatin and 0.2 mmol/L VP-16 for 24 h. The total
RNA was extracted to analyze the apoptosis-associated genes.
2.11. Subcutaneous tumor as xenotransplantation in
nude mice
Six-week-old male nude athymic BALB/c mice were used to
examine tumorigenicity. Sphere clone cells from single CD133+
cell, CD133+ cells, CD133− cells and unselected cells all of
which were isolated from KATO-III cells were injected into the
left axillary subcutaneous tissues of nude mice (n = 5 per group)
(1 × 104 cells in 0.2 mL volume). The outcome indicators were
consisted of the survival rate of mice, the growth rate, the vol-
ume and the mass of xenograft tumors. All animal work was
carried out according to institutional guidelines.
2.12. Statistical analysis
SPSS 16.0 (SPSS Inc, USA) was used for the statistical
analysis. Quantitative data were expressed as mean ± SD and
analyzed by One-way ANOVA or student's t-test. The ratio data
were expressed as percentage and compared using the Fisher's
exact probability test. The survival curves were plotted using the
Kaplan–Meier method and compared using the Log-rank test.
Statistical signiﬁcance was deﬁned as P < 0.05.
3. Results
3.1. CD133 expression in primary lesion of GC in
relation to patients' survival
Based on the immunohistochemistry results, the CD133
positivity rates were 66% (33/50) in primary lesion of GC andProduct size
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Figure 2. Representative graphs of ﬂow cytometry and percentages of
CD133+ subpopulations in KATO-III cells before and after the immuno-
magnetic selection.
A: Unselected KATO-III cells; B: CD133+ cells just following the immu-
nomagnetic selection; C: CD133+ cells at 1 week of serum-free culture
following the immunomagnetic selection.
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CD133+ particles were rarely observed in paired peri-cancer
tissues but were mainly observed on the membrane of tumor
cell in primary lesion of GC (Figure 1A,B). The CD133 mRNA
was found to be increased in GC tissue compared with the paired
peri-cancer tissue (P < 0.001) (Figure 1C,D). Similarly, the
CD133 protein was demonstrated to be elevated in GC tissue
compared with the paired peri-cancer tissue (P < 0.001)
(Figure 1E,F).
For the survival analysis, the average value
(0.6205 ± 0.1119) of CD133 protein expression for GC tissue
with the range of 0.471–0.924 was set as the cut-off. The CD133
expression was 0.542 ± 0.046 for the lower positivity expression
group (n = 25) and 0.728 ± 0.093 for the higher positivity
expression group (n = 25). The Kaplan–Meier survival analysis
showed that the lower CD133+ expression group had a signiﬁ-
cantly better survival compared with the higher CD133+
expression group (P = 0.014) (Figure 1G).
3.2. Enrichment and characterization of CD133+
subpopulation in human GC cells
The percentage of CD133+ cell subpopulation was
(28.0 ± 2.0)% for KATO-III cells (Figure 2A), (16.5 ± 1.5)% for
SGC-7901 cells, (6.0 ± 2.0)% for AGS cells and (4.0 ± 2.0)%
for MKN-45 cells by ﬂow cytometry before IMS and ﬂoating
culture. KATO-III cells were selected to enrich for further ex-
periments. The percentage of CD133+ cell subpopulation was
(91.0 ± 3.0)% (Figure 2B) for CD133+ selection group and
(17.0 ± 4.0)% for CD133− selection group following the IMS.
After 1 week in serum-free culture, the enriched level of
CD133+ cells reached (95.0 ± 2.0)% (Figure 2C) andEBA
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Figure 1. Expression of CD133 in primary lesion of GC and survival curves.
A: Negative expression in peri-cancer tissue by immunohistochemistry; B: P
Electrophoresis bands of CD133 mRNA in primary lesion (n = 50), in pared
dehydrogenase (GPADH) mRNA was used as internal control; D: Bar charts
protein in primary lesion (n = 50), in pared peri-cancerous tissues (n = 50) and G
of primary lesion; G: Survival curves in higher CD133+ expression group and(14.0 ± 6.0)% for CD133+ and CD133− selection groups
respectively. In contrast, to exclude the false inﬂuence of
CD133+ antibody, the isotype-immunoglobulin G labeled in
random control group exhibited CD133+ cell subpopulation
percentages of (1.5 ± 0.5)% and (1.3 ± 0.4)% following the IMS
and then at 1 week after serum-free culture respectively.
3.3. In vitro characterization of CD133+ cells
3.3.1. Clonal sphere-forming capacity
Following the limited dilution, single CD133+ cells
(Figure 3A) proliferated into 2–3 cell clones on Day 3–4
(Figure 3B), a small clone sphere with decade cells on Day 5–6
(Figure 3C) and into larger clone spheres containing several
decades cells on Day 8–9 onwards (Figure 3D). In contrast, the
clonal spheres could not be identiﬁed from the ﬂoating culture of
single CD133− cells after the limited dilution.NO.1-NO.16
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Figure 3. Clonal sphere formation of single CD133+ cell after limited
dilution and growth curves of CD133+ cells and CD133− cells.
E: Comparison of the proliferation capacity of CD133+ cells and CD133−
cells by CCK-8 assay. P< 0.05, CD133+ group vs. CD133− group.
Table 2
Tumorigenic capacity of xenografts-inoculated tumor.
Groups
(n = 5)
Tumorigenic
rate
Mean volume
(mm3)
P
value
Mean mass
(mg)
P
value
Clonal
spheres
100% 718.5 ± 183.3 0.001* 524.4 ± 101.8 0.002*
CD133+
cells
100% 631.5 ± 243.2 0.005* 405.6 ± 126.3 0.008*
Unselected
cells
80% 160.8 ± 135.8 116.7 ± 103.0
CD133−
cells
0% N/A N/A N/A N/A
N/A: Means not applicable; *: Compared with that in the group of un-
selected cells.
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CD133+ cells exhibited a signiﬁcantly higher proliferative
rate compared with CD133− cells (Figure 3E). Meanwhile, the
population doubling time (21 ± 3) h for CD133+ cells was
signiﬁcantly shorter than that for CD133− cells [(40 ± 8) h,
P = 0.001].
3.3.3. Detection of mRNA regarding to stem cell-
associated genes
RT-PCR assay indicated that the mRNA expressions of Sox-
2, Oct-4, Musashi-1 and ABCG2 in CD133+ clonal cell spheres
were signiﬁcantly higher than those in CD133+ cells and
CD133− cells respectively (Figure 4A). And the mRNA
expression of Sox-2, Oct-4, Musashi-1 and ABCG2 in CD133+
cells group were not signiﬁcantly different from those in
CD133− cells group (Figure 4A). However, the mRNA expres-
sion of Nanog and EGFR did not differ signiﬁcantly among
CD133+ clonal cell spheres, CD133+ cells and CD133− cells
(Figure 4A).
3.4. In vivo tumorigenicity
The forming rates of xenograft tumor were 100% for clonal
cells, 100% for CD133+ cells and 80% for unselected cells.
However, xenograft tumor couldn't be formed following the
inoculation of CD133− cells. At 4 weeks following the inocu-
lation, clonal cells group and CD133+ cells group had signiﬁ-
cantly larger average volume and heavier average mass of
xenograft tumor compared with those in the unselected cells
group (Table 2).Sox-2 Bcl-2 (CD133 )
Bcl-2 (CD133 )
Bax (CD133 )
Bax (CD133 )
GAPDH
CD133 CD133
BA
 Blank   5-FU    DDP  VP-16
Clonal 
spheres
Oct-4
ABCG-2
EGFR
Nanog
GAPDH
Musashi-1
Figure 4. Representative mRNA expressions of ABCG2, EGFR, stem cell
markers and apoptosis-associated genes.
A: Representative mRNA expression of ABCG2, EGFR, stem cell markers
in clonal spheres, CD133+ cells and CD133− cells; B: Representative
mRNA expressions of apoptosis-associated genes in CD133+ cell sub-
population and CD133− cell subpopulation. Blank group: Without treat-
ment of anti-tumor agent. GPADH mRNA was used as internal control.The xenograft tumors exhibited a round or oval shape with a
pale as a macroscopic observation. The tumor tissue had more
parenchymal cells but fewer interstitial cells in hematoxylin-
eosine (H&E) section under microscopy. Tumor cells exhibi-
ted a cluster-band pattern with sparse necrotic foci. The tumor
cells had a larger cell volume and abundant cytoplasms. Also,
their cell nuclei had a larger volume and exhibited a poly-
morphic pattern (Figure 5A). Immunohistochemistry against
CD133 showed that the positive granules were mainly located in
cell membrane and cytoplasms (Figure 5B).
3.5. The gene proﬁles regarding apoptosis and growth
inhibition associated with resistance to anti-tumor drug
3.5.1. Among the apoptosis-associated gene proﬁles
Unselected cells, CD133+ and CD133− cells did not signiﬁ-
cantly differ in the mRNA expressions of Bcl-2 and Bax prior to
the treatment. At 12 h following the treatment with anti-tumor
agents, the Bcl-2 mRNA expression decreased, but the Bax
mRNA expression increased signiﬁcantly in unselected cells,
CD133+ cells and CD133− cells compared with those in the
untreated control cells. Among treated cells, the Bcl-2 mRNA
expression was signiﬁcantly higher in CD133+ cells compared
with that in CD133− cells. Whereas the Bax mRNA expression
was signiﬁcantly lower in CD133+ cells compared with that in
CD133− cells (Figure 4B).
3.5.2. Tumor cell growth inhibition
The treated KATO-III cells exhibited growth suppression
in the presence of chemotherapeutic agents of various con-
centrations compared with untreated control cells. At 12 hBA
100 μm100 μm
Figure 5. Microscopic observations with H&E staining and CD133
immunohistochemical staining on xenogeneic tumor by transplantation of
CD133+ cells in nude mice.
A: H&E staining proﬁles of the xenograft tumor; B: CD133+ proﬁles in the
xenograft tumor by immunohistochemical staining; Black arrow: CD133+
cells.
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CD133+ and CD133− cells exhibited an apoptosis-associated
morphological alteration. At 48 h following the treatment,
the number of apoptotic cells increased. Within the concen-
tration range of 5–20 mmol/L for 5-FU and cisplatin and 0.1–
0.4 mmol/L for VP-16, the number of apoptotic cells
increased with the concentration elevated. Furthermore,
CD133+ and CD133− cells exhibited a similarly cellule
morphology.
With the elevated doses of FU, cisplatin or VP-16, the
growth inhibition rate of either CD133+ cells or CD133− cells
gradually increased while CD133+ cells exhibited a signiﬁ-
cantly lower growth inhibition rate compared with CD133−
cells at 12 h following the treatment of anti-tumor agents
(Table 3).Table 3
Growth inhibition rates of CD133+ cells and CD133− cells by CCK-8
assessment under the treatment of 5-FU, cisplatin or VP-16.
Mean ± SD, n = 4.
Anti-tumor
agents
Concentrations CD133+ CD133− P value
5-FU
(mmol/L)
5 30.56 ± 1.99 32.81 ± 2.67 0.045
10 33.48 ± 2.32 45.87 ± 3.58 0.049
15 67.52 ± 4.51 78.97 ± 2.88 0.045
20 88.60 ± 1.95 95.73 ± 2.12 0.046
Cisplatin
(mmol/L)
5 45.89 ± 3.64 50.21 ± 3.22 0.043
10 60.83 ± 2.60 73.36 ± 1.72 0.049
15 75.19 ± 2.22 82.29 ± 2.01 0.048
20 81.20 ± 1.18 90.46 ± 1.89 0.049
VP-16
(mmol/L)
100 37.21 ± 3.80 35.55 ± 3.23 0.048
200 40.59 ± 5.82 43.02 ± 4.36 0.051
300 59.33 ± 2.02 70.21 ± 2.35 0.042
400 78.49 ± 3.22 89.32 ± 3.54 0.0474. Discussion
The investigation into gastric mucosal epithelial cytokinetics,
precancerous lesion, gastric microcancer and morphologically
variable GC cells raises the doubt over the previous theory
regarding the pathogenesis of GC. The histological origin of GC
is still unclear. It is likely to derive from a single cell, namely,
primitive stem cell, located in the granular isthmus [23]. Primitive
stem cells are multipotent, whilst pro-cancerous factors and
tumorigenicity process vary greatly. Therefore, GC exhibits a
highly variable morphology and biological behavior.
Normal gastric epithelial stem cells or progenitor cells are
primitive cells that are self-renewable and multiplicative as adult
stem cells in some proﬁles. Gastric epithelial pluripotent stem
cells differentiate into progenitor cells and further into various
types of differentiated cells. This property plays an important
role in gastric mucosal regeneration and homeostasis mainte-
nance [24]. It is proposed in the theory of TICs that they may be
originated from normal stem cells or pro-cancerous progenitor
cells with cumulative genetic mutations [4]. TICs may differ
from normal epithelial stem cells or progenitor cells in
biological behavior and phenotype, but they are self-
renewable, unlimitedly proliferative and multipotent [25]. As
target cells with cumulative genetic mutations, TICs play an
essential role in the very early stage of GC oncogenesis and
are thought to cause abnormal proliferation, invasion and
metastasis of GC [26].Multiple cell markers are currently available for the identi-
ﬁcation of stem cells-like TICs. Various tumor precursor cells,
especially of epithelial origin, highly express CD133, though
tumor precursor cells in various tissues vary in phenotype [7–17].
The CD133 protein is located in the cell membrane projections
and is involved in the formation of cell membrane topology.
Meanwhile, the expression level of CD133 decreases rapidly
along with the cell differentiation. Therefore, CD133 could be
considered probably to be a molecular marker for the
enrichment of stemness cells for further identiﬁcation of them
[27]. While CD133 is well documented as a pivotal TICs
surface marker in current literature [28,29], TICs share identical
surface markers with stemness cells from the perspective of
histological origin.
Our previous study showed that CD133+ cells existed in the
tumor thrombi of primary GC vessels [30,31]. The expression
level of CD133 mRNA has been revealed to be positively
correlated with the lymph node metastasis but negatively
associated with the expression level of Ki-67, a marker of tu-
mor cell proliferation [16,30,31]. Therefore, it can be hypothesized
that GC CD133+ cell subpopulation could contain static primary
and secondary TICs that may be more likely to be metastatic [32].
The upregulated CD133 expression is believed to be essential
for the maintenance of gastrointestinal epithelial stem cells.
CD133 is found to be expressed on the cell surface as well as
projections at the bottom of crypt, where it is thought to harbor
stem cells [15]. Moreover, anti-CD133 antibody combined with
chemotherapeutic agents antagonizes CD133 receptor and sup-
presses the in vitro proliferation of GC cells. Furthermore, it
suppresses the xenograft tumor survival in nude mice [15].
Therefore, GC CD133+ cells are potential tumorigenic TICs in
some extent.
This investigation demonstrated that CD133 mRNA and
protein were signiﬁcantly higher in GC tissues compared with
those in peri-cancer tissues of GC. Furthermore, among four
GC cell lines, KATO-III cells had the highest percentage of
CD133+ cell subpopulation, which enabled the establishment of
a high-purity CD133+ cell subpopulation following their sepa-
ration for further investigation of their biological features. IMS
rendered the efﬁcient enrichment of CD133+ cell subpopulation
from KATO-III cells. Following this separation, the percentage
of CD133+ cell subpopulation reached up to 90%. The selected
cells exhibited no compromise in cell vitality. IMS overcame
the technical drawbacks of ﬂow cytometry, namely, cell
contamination and reduced cell viability. The biological char-
acteristics of GC cell lines with varying differentiation grade are
yet to be studied regarding the percentage of CD133+ cell
subpopulation.
The propagation of TICs was the primary step for the
investigation of TICs characteristics and was essential for the
puriﬁcation of TICs. Unlike conventional culture of passaged
tumor cells, serum-free ﬂoating culture supplemented with EGF
and bFGF was used to prevent tumor stem cells from differen-
tiation in the process of culture and propagation. The bFGF is
known to promote the asymmetric division of neural stem cells,
which are self-renewable and responsive to EGF. In the presence
of EGF, EGF-responsive stem cells are self-replicative to pro-
duce secondary bFGF-responsive neural stem cells through
mitosis and asymmetric division [8,33,34]. Singh et al. isolated
sphere cells from neuroepithelial tumor using serum-free cul-
ture media [8]. These cells were characteristic of tumor stem
cells. Moreover, tumor stem cells have been identiﬁed in
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proliferative than CD133− cells, could be maintained, which
suggested that differentiating tumor cells became apoptotic in
the serum-free ﬂoating culture supplemented with growth fac-
tors. However, non-differentiable TICs maintained self-renewal
and undifferentiation through asymmetric division. Following
the supplementation of serum, CD133+ cells decreased in
number, emerged sparsely distributed, became adherent and
became morphologically senescent. Moreover, CD133+ cells
turned from single cells into cell spheres containing dozens of
cells within two weeks following further in vitro clonal cell
culture, which showed that selected CD133+ cell subpopulation
might have stem cells-like self-renewal and clone-forming po-
tential. The phenomenon of clonal cell spheres derived from
single cell with CD133+ demonstrated that the clonal cell
spheres mainly consisted of CD133+ cell subpopulation. These
clonal cell spheres shared similar or even stronger proliferative
potential compared with CD133+ cell subpopulation.
The investigation of the mechanism of embryonic stem cell
(ESC) self-renewal showed that Oct-4, Nanog and Sox-2 tran-
scription factors formed a core regulatory ring controlling the
transcription of 2260 mRNAs through modulating 16 major
regulatory genes. These transcription factors contained an ESC-
speciﬁc functional genome [35]. Selective knockdown of any
gene located in this core regulatory ring resulted in the loss of
ESC self-renewal but didn't disable their differentiation [36,37].
It has been reported that Msi-1 might be a surface marker of
gastrointestinal epithelial stem cells and progenitor cells, which
is assumed to maintain the undifferentiation of stem cells
through the post-transcriptional translation [38,39]. The present
study of ours may be the ﬁrst report regarding the above
mentioned stem cell markers in CD133+ cell subpopulation
from KATO-III cells. Meanwhile, both CD133+ cell subpopu-
lation and its clonal spheres expressed Msi-1 and EGFR.
Additionally, CD133+ clonal sphere cells expressed higher
mRNA levels of Oct-4, Sox-2 and Musashi-1 compared with
those in either CD133+ cells or CD133− cell, which did not
differ between CD133+ cells and CD133− cells. All of these
suggested that CD133+ cell subpopulation might derive from
stem cells of a single clone with colony-forming and replicative
potential in GC cell lines in vitro and that CD133+ clonal sphere
cells might be classiﬁed as cancer stem cell while CD133+ cells
not existing in clonal sphere could not classiﬁed as cancer stem
cell. There were not enough evidences demonstrating CD133+
cells as cancer stem cells in this study, though CD133+ cells not
existing in clonal sphere shared some biological speciﬁcity like
cancer stem cells in vitro and in vivo. This phenomenon indi-
cated that some part of CD133+ cells in clonal spheres being
able to form clonal sphere possessed the ability of self-renewal
and another part of them being able to differentiate relative
matured cells with the loss of stem cell markers.
The tumorigenicity of TICs should be evaluated with regard
to two aspects, in vitro clone-forming potential and in vivo
xenograft tumor formation in immunodeﬁcient animals [8]. This
study determined the potent tumorigenicity of GC CD133+ cells.
Selected CD133+ cells rendered the formation of xenograft
tumor at the dose of 1 × 104 cells per animal, whereas
CD133− cells could not form xenograft tumor. Further
histological studies showed that CD133+ cell subpopulation
existed in the xenograft tumor similar to that in human
primary GC tissue and that the patients’ survival in lower
CD133+ protein expression group was better than that inhigher CD133+ protein expression group. Additionally, the
analysis of xenograft tumor growth rate, volume and mass
demonstrated that CD133+ cells were more tumorigenic than
unselected cells. These ﬁndings revealed that CD133+ and
CD133− cells differed in tumorigenicity with CD133+ cells
probably containing more TICs.
One of the problems regarding chemotherapy is that the
untreated or recurrent tumors are primarily insensitive to anti-
neoplastic or resistant to anti-tumor agents, which has prelimi-
narily been investigated in the regulation of apoptosis-associated
genes. This leads to many difﬁculties in our efforts to improve
cancer patient survival. TICs usually remain static and intrinsi-
cally resistant though DNA self-repair and the action of ABC
transport protein. Cross resistance emerges with anti-tumor
agents with varying structure and mechanism of action [40,41].
Moreover, the resistance occurs in TICs and similar offspring
cells through point mutation, genetic activation or gene
ampliﬁcation following the exposure to irradiation or pro-
cancerous factor [42].
The investigation of chemotherapy resistance in solid tumors
associated with TICs shows that TICs are more resistant to
chemotherapeutic agents than other tumor cells at rapid prolif-
eration phase. TICs and offspring cells can proliferate in recur-
rent patients following chemotherapy or multi-drug resistant cell
populations [43]. Additionally, multiple apoptosis-associated
genes, such as Bcl-2, Bax, nuclear factor kB, mutant p53 and
c-myc are all involved in tumor cell resistance [44–46].
Of chemotherapeutic agents, cell cycle speciﬁc agents refer to
chemotherapeutic agents to which cells with speciﬁc phases
(other than G0-phase) are sensitive. Both 5-FU and VP-16
belong to cell cycle speciﬁc agents. The former agent acts on
tumor cells at each phase of cell division, whereas the latter
works on tumor cells at late S- or G2-phase. As a cell cycle
nonspeciﬁc agent, cisplatin targets at both proliferative and non-
proliferative cell stages. The study on the resistance of KATO-
III cells to these three agents in this investigation of ours
showed that CD133+ cell subpopulation had a signiﬁcantly
lower ability in the suppression rate of cell growth compared
with that in CD133− cell subpopulation. Moreover, ABCG2, a
resistance-associated gene, was expressed in CD133+ cell sub-
population. Following the treatment with chemotherapeutic
agents, anti-apoptotic Bcl-2 mRNA expression was down-
regulated but pro-apoptotic Bax mRNA expression was up-
regulated in CD133+ cells.
In conclusion, the patients of GC with lower CD133+
expression shared better survival in comparison with that in
higher CD133+ expression. CD133+ cells, especially in CD133+
clonal spheres with higher mRNA expressions of Oct-4 and Sox-
2, shared stronger ability in proliferation, clone-forming poten-
tial, differentiable capability, tumorigenicity and resistant to
chemotherapeutic agents probably regulated by Bcl-2 and Bax.
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